Transfusion-related acute lung injury (TRALI): a retrospective review of reported cases in Queensland, Australia over 20 years.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
25
01
2022
accepted:
03
06
2022
pubmed:
16
8
2022
medline:
15
12
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
Transfusion-related acute lung injury (TRALI) is a rare but potentially fatal transfusion reaction. An effective haemovigilance programme is important in implementing successful and targeted risk reduction strategies. We aim to provide a summary of TRALI cases referred for investigation in Queensland (QLD) Australia from 1999 to 2019, describing the epidemiological and laboratory features of local TRALI cases. A retrospective audit evaluated all cases reported to the QLD Australian Red Cross Lifeblood over the 20-year study period. Cases were categorised according to the 2004 Canadian consensus criteria. Of the 91 cases referred for investigation, expert review confirmed 30 of TRALI and 18 of possible TRALI. A total of 238 donors and 110 blood products were assessed in confirmed cases. TRALI affected patients of all ages. Most patients had underlying haematological malignancies (25%), surgery (15%) or liver disease (13%). TRALI incidence was measured at 1 in 130,000 per issued product in QLD. Red cells were transfused in 32 cases, platelets in 18 and plasma products in 21, with 16 cases involving multiple products. Following laboratory assessment, 23% of cases had findings supportive of antibody mediated TRALI and 21% as likely non-antibody mediated. Possible TRALI was identified in 37.5% of cases of which 25% were antibody mediated and 12.5% non-antibody mediated. Nine (18.5%) cases were uncategorised due to insufficient immunologic investigations. Rates of TRALI incidence measured are lower than those seen in many international studies. A reduction in confirmed cases has been noted over recent years, supporting the implementation of risk-reduction strategies. We report a relatively higher proportion of non-antibody mediated TRALI and possible TRALI cases in more recent years, suggesting the need to further understand the role of product age and biological risk modifiers.
Sections du résumé
BACKGROUND
Transfusion-related acute lung injury (TRALI) is a rare but potentially fatal transfusion reaction. An effective haemovigilance programme is important in implementing successful and targeted risk reduction strategies. We aim to provide a summary of TRALI cases referred for investigation in Queensland (QLD) Australia from 1999 to 2019, describing the epidemiological and laboratory features of local TRALI cases.
MATERIALS AND METHODS
A retrospective audit evaluated all cases reported to the QLD Australian Red Cross Lifeblood over the 20-year study period. Cases were categorised according to the 2004 Canadian consensus criteria.
RESULTS
Of the 91 cases referred for investigation, expert review confirmed 30 of TRALI and 18 of possible TRALI. A total of 238 donors and 110 blood products were assessed in confirmed cases. TRALI affected patients of all ages. Most patients had underlying haematological malignancies (25%), surgery (15%) or liver disease (13%). TRALI incidence was measured at 1 in 130,000 per issued product in QLD. Red cells were transfused in 32 cases, platelets in 18 and plasma products in 21, with 16 cases involving multiple products. Following laboratory assessment, 23% of cases had findings supportive of antibody mediated TRALI and 21% as likely non-antibody mediated. Possible TRALI was identified in 37.5% of cases of which 25% were antibody mediated and 12.5% non-antibody mediated. Nine (18.5%) cases were uncategorised due to insufficient immunologic investigations.
DISCUSSION
Rates of TRALI incidence measured are lower than those seen in many international studies. A reduction in confirmed cases has been noted over recent years, supporting the implementation of risk-reduction strategies. We report a relatively higher proportion of non-antibody mediated TRALI and possible TRALI cases in more recent years, suggesting the need to further understand the role of product age and biological risk modifiers.
Identifiants
pubmed: 35969142
pii: 2022.0020-22
doi: 10.2450/2022.0020-22
pmc: PMC9726622
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
454-464Références
Crit Care Med. 2010 Mar;38(3):771-8
pubmed: 20035217
Vox Sang. 2013 Feb;104(2):127-34
pubmed: 22892067
Transfusion. 2011 Dec;51(12):2549-54
pubmed: 21615744
Crit Care Med. 2014 Jul;42(7):1676-87
pubmed: 24776608
Vox Sang. 2012 May;102(4):317-23
pubmed: 21967322
Crit Care Med. 2006 May;34(5 Suppl):S124-31
pubmed: 16617256
Transfusion. 2008 Oct;48(10):2167-76
pubmed: 18564387
Blood. 2012 Feb 16;119(7):1757-67
pubmed: 22117051
Transfusion. 2001 Oct;41(10):1244-8
pubmed: 11606823
Transfusion. 2010 Jan;50(1):213-20
pubmed: 19694998
Hematol Transfus Cell Ther. 2020 Oct - Dec;42(4):326-332
pubmed: 31838025
Transfusion. 2009 Mar;49(3):440-52
pubmed: 18980623
Br J Haematol. 2015 Sep;170(5):597-614
pubmed: 25921271
Blood Rev. 2022 May;53:100926
pubmed: 35065815
Blood Adv. 2021 Oct 26;5(20):3975-3985
pubmed: 34438443
Am J Respir Crit Care Med. 2007 Nov 1;176(9):886-91
pubmed: 17626910
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):585-594
pubmed: 30570487
Am J Clin Pathol. 2005 Oct;124(4):601-9
pubmed: 16146824
Best Pract Res Clin Anaesthesiol. 2007 Jun;21(2):183-93
pubmed: 17650771
Transfusion. 2011 Oct;51(10):2102-10
pubmed: 21382042
Transfusion. 2019 Aug;59(8):2567-2574
pubmed: 31145481
Transfus Med. 2008 Oct;18(5):276-80
pubmed: 18937733
Lancet. 2013 Sep 14;382(9896):984-94
pubmed: 23642914
Vox Sang. 2008 Nov;95(4):313-7
pubmed: 19138261
Crit Care Med. 2006 May;34(5 Suppl):S114-7
pubmed: 16617254
Vox Sang. 2015 May;108(4):387-92
pubmed: 25753261
Vox Sang. 2007 Jul;93(1):70-7
pubmed: 17547568
Transfusion. 2007 Apr;47(4):599-607
pubmed: 17381617
Transfusion. 2019 Jul;59(7):2465-2476
pubmed: 30993745
Blood. 2003 Jan 15;101(2):454-62
pubmed: 12393667
Transfusion. 1985 Nov-Dec;25(6):573-7
pubmed: 4071603
Transfusion. 2017 Oct;57(10):2373-2380
pubmed: 28703861
Br J Haematol. 2009 Nov;147(4):431-43
pubmed: 19663827
Br J Anaesth. 2003 May;90(5):573-6
pubmed: 12697582
Transfus Med Rev. 2018 Jan;32(1):16-27
pubmed: 28864336
Transfus Med Hemother. 2008;35(2):89-91
pubmed: 21512633
Transfusion. 2004 Dec;44(12):1774-89
pubmed: 15584994
Asian J Transfus Sci. 2020 Jul-Dec;14(2):126-130
pubmed: 33767538
Intern Med J. 2003 Jul;33(7):286-90
pubmed: 12823673
Transfus Med Rev. 2006 Oct;20(4):273-82
pubmed: 17008165